Clinical Trial Update: Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial assessing a PD-1 inhibitor combined with stereotactic radiation for recurrent glioblastoma; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• PD-1 inhibitor (anti-PD-1 immunotherapy)

Snippet

Sponsor: Chirag G. Patil | Conditions: Glioblastoma Multiforme | Phase 1, Phase 2 | Status: RECRUITING